Clinical Safety, Tolerance, and Plasma Levels of the Oral Anticholinesterase 1,2,3,4‐Tetrahydro‐9‐aminoacridin‐1‐oL‐maleate (HP 029) in Alzheimer's Disease: Preliminary Findings

Abstract

HP 029 (1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate), an oral anticholinesterase, enhances memory in rodents and may be useful in treating Alzheimer's disease (AD). To assess adverse events in relation to dosage and plasma drug levels, 24 hospitalized AD subjects were randomly assigned to receive placebo or HP 029 for 10 days in a double-blind, sequential escalation study. Maximum daily dosages were 450 mg (group 1), 300 mg (group 2), and 225 mg (group 3), divided into three doses per day. The group 1 trial was discontinued on day 5 because one subject, 6 hours following the second of three scheduled 150-mg doses, had a tonic seizure after protracted vomiting and hyperventilation; adverse events in other patients included nausea, vomiting, abdominal cramps, diarrhea, dizziness, and syncope. Adverse events were generally less severe in group 2, but only two of six HP 029 subjects could complete the trial at 300 mg/day. All group 3 subjects completed the trial at 225 mg/day with drug related, mild adverse events (nausea, vomiting, lacrimation, rhinorrhea) in only two subjects. Although mean plasma drug levels were related to adverse events across dosage groups, they did not adequately predict the occurrence or severity of adverse events in individual subjects. The 225 mg/day dose appears to be safe for use in multicenter outpatient trials of HP 029 efficacy in AD. Further patient studies are ongoing to determine the relation of specific subject characteristics to the metabolic profile of HP 029 and biological response.

Research on the Cognitively Impaired: Lessons and Warnings from the Emergency Research Debate

“…Much like the practice of emergency research before the controversy that essentially halted it, clinical researchers construe from existing regulations and guidelines practices that seem appropriate. Even a brief review of published research on demented subjects reveals that researchers obtain consent from a variety of individuals in addition to, or even instead of, the subject 19–23,51–54 . These practices include consent from the subject's caregiver, legally authorized representative, or family member.…”

Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study

“…Thus, a panel of eight AD patients (6 on drug, 2 on placebo) was titrated up to 150 tid (450 mg per day) over a period of 4 days [21]. However, after the second 150 mg dose a single clonic/tonic seizure occurred in one subject, and the panel was discontinued.…”

Maximum Tolerated Dose Evaluation of the AMPA Modulator Org 26576 in Healthy Volunteers and Depressed Patients

“…[2,17] Furthermore, conflicting outcomes within the same drug class (e.g. acetylcholinesterase inhibitors)[12,17] suggest that specific molecule differences may play a contributory role. Such divergent findings underscore the importance of carefully evaluating tolerability in the target population prior to embarking on phase II efficacy trials of any new investigational drug.…”